New biomarker identified to diagnose Alzheimer’s in asymptomatic stages – Medical Xpress

3 minutes, 59 seconds Read

New biomarker identified to diagnose Alzheimer’s in asymptomatic stages

New biomarker to diagnose Alzheimer's in asymptomatic stages
Light microscopy image of a section of post-mortem human frontal cortex from a patient with Braak grade VI (most advanced) Alzheimer’s disease. Neurons with high levels of tau protein can be seen. Credit: Institute for Bioengineering of Catalonia (IBEC)

A study has identified a new biomarker for Alzheimer’s disease in asymptomatic stages of the disease. The molecule is miR-519a-3p, a microRNA directly linked to the expression of the cellular prion protein (PrPC), which is deregulated in people suffering from some neurodegenerative diseases such as Alzheimer’s.

The study, led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona, is published in the journal Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease.

The search for biomarkers that are stable and easily detectable in biofluids, such as microRNAs, offers hope for detecting Alzheimer’s disease in its early, asymptomatic stages. Early detection could significantly improve the diagnosis and treatment of this disease, which affects more than 35 million people worldwide.

First link between miR-519a-3p and PrPC in Alzheimer’s disease

The expression of some microRNAs is known to be deregulated in Alzheimer’s patients. However, this is the first time that this microRNA has been specifically linked to the decrease in cellular prion protein production during .

“Currently, tests to diagnose Alzheimer’s disease are usually carried out after the onset of symptoms, when there is already underlying cognitive impairment. We believe that the detection of this microRNA may help to establish additional criteria for a more accurate diagnosis in the early stages of the disease,” explains IBEC principal investigator José Antonio del Río, full professor at the Faculty of Biology and the Institute of Neurosciences of the University of Barcelona (UB) and co-leader of the study.

The study also comparatively analyzes the presence of the biomarker in samples from other .

“If our goal is to use miR-519a-3p as a biomarker to detect Alzheimer’s dementia in hypothetically healthy people, it is essential to ensure that its levels are not altered in other neurodegenerative diseases. In our study, we compared the levels of this biomarker in samples from other tauopathies and Parkinson’s disease, confirming that the changes in miR-519a-3p are specific to Alzheimer’s disease,” said IBEC senior researcher Rosalina Gavín, UB associate professor and co-leader of the study.

Dayaneth Jácome, a researcher in del Río’s group and first author of the study, says that the team is making progress. The next step is to validate miR-519a-3p as a biomarker in from different cohorts of patients, in order to start using it in the clinical diagnosis of Alzheimer’s disease in peripheral samples.

The researchers are members of the Center for Networked Biomedical Research in Neurodegenerative Diseases, CIBERNED.

MicroRNAs: Gene silencers

The amount of cellular prion protein changes over the course of Alzheimer’s disease, with higher levels in the early stages of the disease and lower levels as the disease progresses. Although the mechanism responsible for these changes is not known in detail, it has been observed that certain microRNAs bind to a specific region of the PRNP gene that controls PrPC expression, reducing it.

For this reason, and based on comparisons of previous studies and computational analyzes in various genomic databases, the researchers selected the microRNA miR-519a-3p for their study.

More information:
Dayaneth Jácome et al, miR-519a-3p, found to regulate cellular prion protein during Alzheimer’s disease pathogenesis, as a biomarker of asymptomatic stages, Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease (2024). DOI: 10.1016/j.bbadis.2024.167187

Provided by
Institute for Bioengineering of Catalonia (IBEC)

New biomarker identified to diagnose Alzheimer’s in asymptomatic stages (2024, May 15)
retrieved 16 May 2024

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Alzheimer’s and Parkinson’s biomarkers show promise for early diagnosis


Feedback to editors

This post was originally published on 3rd party site mentioned in the title this site

Similar Posts